{"id":7955,"date":"2026-04-30T08:30:48","date_gmt":"2026-04-30T15:30:48","guid":{"rendered":"https:\/\/rakuten-med.com\/us\/?post_type=press_releases&#038;p=7955"},"modified":"2026-04-29T22:25:35","modified_gmt":"2026-04-30T05:25:35","slug":"rakuten-medical-announces-two-poster-presentations-and-exhibit-booth-at-asco-2026-annual-meeting","status":"publish","type":"press_releases","link":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/","title":{"rendered":"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting"},"content":{"rendered":"<div id=\"pl-7955\"  class=\"panel-layout\" ><div id=\"pg-7955-0\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7955-0-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7955-0-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<ul>\n<li><b><i>First presentation of results from a global Phase 3 study of ASP-1929 photoimmunotherapy as monotherapy in locoregional recurrent head and neck squamous cell carcinomas (HNSCC)\u00a0<\/i><\/b><\/li>\n<li><b><i>Real\u2011world Japanese multicenter data on photoimmunotherapy in recurrent nasopharyngeal carcinoma<\/i><\/b><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Disclaimer: Rakuten Medical\u2019s Alluminox\u00ae platform-based photoimmunotherapy is investigational outside Japan.<\/span><\/i><\/p>\n<p><b>SAN DIEGO \u2014 April 30, 2026 \u2014 <\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc., a global biotechnology company developing and commercializing the Alluminox platform-based photoimmunotherapy, today announced that two abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago from May 29 - June 2, 2026.<\/span><\/p>\n<p><span style=\"font-weight: 400\">One poster will feature the first presentation of safety and efficacy data from Rakuten Medical\u2019s global Phase 3, randomized, double-arm, open-label, controlled study (ASP-1929-301; <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT03769506\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">NCT03769506<\/span><\/a><span style=\"font-weight: 400\">) evaluating ASP-1929 photoimmunotherapy for locoregional, recurrent HNSCC.<\/span> <span style=\"font-weight: 400\">This ASP-1929-301 study was conducted at 40 facilities across the U.S., Taiwan, Japan, India, and Ukraine.<\/span><\/p>\n<p><span style=\"font-weight: 400\">Another poster, authored by a research team of Japanese physicians, will present the latest findings from an investigator-initiated multicenter observational study evaluating the efficacy and safety of photoimmunotherapy for recurrent nasopharyngeal cancer in clinical practice in Japan.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400\">Rakuten Medical will also have a booth in the Exhibit Hall. The Company medical team will be pleased to welcome ASCO participants at booth #37147.<\/span><\/p>\n<p><span style=\"text-decoration: underline\"><b>Poster Presentation for ASP-1929-301 Study:<\/b><\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>Abstract Title:<\/b><span style=\"font-weight: 400\"> A phase 3, randomized, double-arm, open-label, controlled study of ASP-1929 photoimmunotherapy (PIT) versus physician\u2019s choice standard of care (SOC) for patients with locoregional, recurrent head and neck squamous cell carcinoma (HNSCC)<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Abstract Number:<\/b><span style=\"font-weight: 400\"> 6080<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Abstract Link:<\/b> <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/261461\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/www.asco.org\/abstracts-presentations\/261461<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>Session Name:<\/b><span style=\"font-weight: 400\"> Poster Session \u2013 Head and Neck Cancer<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Session Date:<\/b><span style=\"font-weight: 400\"> Saturday, May 30, 2026<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Session Time:<\/b><span style=\"font-weight: 400\"> 1:30 p.m. \u2013 4:30 p.m., CDT<\/span><\/li>\n<li style=\"font-weight: 400\"><b>First Author:<\/b><span style=\"font-weight: 400\"> Anastasios Maniakas, Assistant Professor of Head and Neck Surgery at The University of Texas MD Anderson Cancer Center<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Location:<\/b><span style=\"font-weight: 400\"> Exhibit Hall A, Poster Board #537<\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><b>Poster Presentation for Real\u2011World Japanese Multicenter Data:<\/b><\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>Abstract Title:<\/b><span style=\"font-weight: 400\"> Real-world efficacy and safety of photoimmunotherapy for recurrent nasopharyngeal carcinoma: A nationwide multicenter study in Japan<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Abstract Number:<\/b><span style=\"font-weight: 400\"> 6030<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Abstract Link:<\/b> <a href=\"https:\/\/www.asco.org\/abstracts-presentations\/263351\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">https:\/\/www.asco.org\/abstracts-presentations\/263351<\/span><\/a><\/li>\n<li style=\"font-weight: 400\"><b>Session Name:<\/b><span style=\"font-weight: 400\"> Poster Session \u2013 Head and Neck Cancer<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Session Date:<\/b><span style=\"font-weight: 400\"> Saturday, May 30, 2026<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Session Time:<\/b><span style=\"font-weight: 400\"> 1:30 p.m. \u2013 4:30 p.m., CDT<\/span><\/li>\n<li style=\"font-weight: 400\"><b>First Author:<\/b><span style=\"font-weight: 400\"> Hideki Tanaka, Department of Otolaryngology, Head and Neck Surgery, Tokyo Medical University<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Location:<\/b><span style=\"font-weight: 400\"> Exhibit Hall A, Poster Board #384<\/span><\/li>\n<\/ul>\n<p><span style=\"text-decoration: underline\"><b>Rakuten Medical Booth:<\/b><\/span><\/p>\n<ul>\n<li style=\"font-weight: 400\"><b>Location:<\/b><span style=\"font-weight: 400\"> Exhibit Hall A, Booth #37147<\/span><\/li>\n<li style=\"font-weight: 400\"><b>Exhibit Dates:<\/b><span style=\"font-weight: 400\"> Saturday \u2013 Monday, May 30 - June 1, 2026<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400\">For more information and updates, please follow Rakuten Medical on <\/span><a href=\"https:\/\/www.linkedin.com\/company\/rakuten-medical\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400\">LinkedIn<\/span><\/a><span style=\"font-weight: 400\"> or visit Rakuten Medical\u2019s booth at ASCO 2026. <\/span><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><div id=\"pg-7955-1\"  class=\"panel-grid panel-no-style\"  style=\"margin-bottom: 0px\" ><div id=\"pgc-7955-1-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7955-1-0-0\" class=\"so-panel widget widget_sow-editor panel-first-child panel-last-child\" data-index=\"1\" ><div class=\"panel-widget-style panel-widget-style-for-7955-1-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-editor so-widget-sow-editor-base\"\n\t\t\t\n\t\t>\n<div class=\"siteorigin-widget-tinymce textwidget\">\n\t<p><b>About Alluminox\u00ae platform<br \/>\n<\/b><span style=\"font-weight: 400\">The Alluminox\u00ae platform is Rakuten Medical\u2019s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye\u00ae 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical\u2019s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and\/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical\u2019s Alluminox platform-based photoimmunotherapy is investigational.\u00a0<\/span><\/p>\n<p><b>About ASP-1929<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical\u2019s first pipeline drug developed on its Alluminox\u00ae platform is ASP-1929, an antibody-dye conjugate comprised of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab and IRDye\u00ae 700DX, a light activatable dye. ASP-1929 binds to EGFR, a cancer antigen expressed in multiple types of solid tumors, including head and neck, breast, lung, colorectal, prostate and pancreatic cancers. After binding to cancer cells, ASP-1929 is locally activated by illumination with red light (690 nm), emitted by a laser device system to produce a photochemical reaction. This reaction is believed to cause damage to the membrane of cancer cells, leading to selective necrosis of cancer cells. In Japan, ASP-1929 received marketing approval from the Japanese Ministry of Health, Labor, and Welfare for unresectable locally advanced or recurrent head and neck cancer in September 2020, under the Sakigake Designation System and the Conditional Early Approval System. ASP-1929 photoimmunotherapy in combination with pembrolizumab is currently under investigation in a global Phase 3 clinical trial as a first-line therapy for recurrent head and neck cancer. Outside Japan, ASP-1929 has not yet been approved for commercial use by any regulatory authority.<\/span><\/p>\n<p><b>About Rakuten Medical, Inc.<br \/>\n<\/b><span style=\"font-weight: 400\">Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox\u00ae platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical\u2019s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries\/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit <\/span><a href=\"http:\/\/www.rakuten-med.com\"><span style=\"font-weight: 400\">www.rakuten-med.com<\/span><\/a><span style=\"font-weight: 400\">.\u00a0<\/span><\/p>\n<p><b>Media &amp; Investor Contact:<br \/>\n<\/b><span style=\"font-weight: 400\">Ai Yoshikawa<br \/>\n<\/span><span style=\"font-weight: 400\">Associate Director, Global Corporate Communications &amp; Investor Relations<br \/>\n<\/span><span style=\"font-weight: 400\">Tel: +81-(0)70-4196-0845<br \/>\n<\/span><span style=\"font-weight: 400\">Email: <\/span><a href=\"mailto:ai.yoshikawa@rakuten-med.com\"><span style=\"font-weight: 400\">ai.yoshikawa@rakuten-med.com<\/span><\/a><\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div><div id=\"pg-7955-2\"  class=\"panel-grid panel-no-style\" ><div id=\"pgc-7955-2-0\"  class=\"panel-grid-cell\" ><div id=\"panel-7955-2-0-0\" class=\"so-panel widget widget_sow-button panel-first-child panel-last-child\" data-index=\"2\" ><div style=\"padding: 30px 0px 0px 0px;\" class=\"panel-widget-style panel-widget-style-for-7955-2-0-0\" ><div\n\t\t\t\n\t\t\tclass=\"so-widget-sow-button so-widget-sow-button-flat-6fd36f18507f-7955\"\n\t\t\t\n\t\t><div class=\"ow-button-base ow-button-align-center\"\n>\n\t\t\t<a\n\t\t\t\t\thref=\"https:\/\/rakuten-med.com\/us\/contact\/\"\n\t\t\t\t\tclass=\"rakuten-btn sowb-button ow-icon-placement-left ow-button-hover\" \t>\n\t\t<span>\n\t\t\t\n\t\t\tContact Us\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>First presentation of results from a global Phase 3 study of ASP-1929 photoimmunotherapy as monotherapy in locoregional recurrent head and [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7955","1":"press_releases","2":"type-press_releases","3":"status-publish","5":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"First presentation of results from a global Phase 3 study of ASP-1929 photoimmunotherapy as monotherapy in locoregional recurrent head and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2026\\\/04\\\/30\\\/7955\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2026\\\/04\\\/30\\\/7955\\\/\",\"name\":\"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"datePublished\":\"2026-04-30T15:30:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2026\\\/04\\\/30\\\/7955\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2026\\\/04\\\/30\\\/7955\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/press-releases\\\/2026\\\/04\\\/30\\\/7955\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.","og_description":"First presentation of results from a global Phase 3 study of ASP-1929 photoimmunotherapy as monotherapy in locoregional recurrent head and [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/","og_site_name":"Rakuten Medical - To conquer cancer.","og_image":[{"width":1500,"height":900,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/","url":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/","name":"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"datePublished":"2026-04-30T15:30:48+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/press-releases\/2026\/04\/30\/7955\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten Medical Announces Two Poster Presentations and Exhibit Booth at ASCO 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases\/7955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/press_releases"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/4"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}